Anticoagulation for stroke prevention after embolic stroke of undetermined source of presumably cardiac source: The sail to Ithaca

Published:October 26, 2021DOI:https://doi.org/10.1016/j.ejim.2021.09.022
      During the last decade, the term embolic stroke of undetermined source (ESUS) was introduced in a pursue to standardized diagnostic workup in a more targeted sub-population of cryptogenic stroke patients [
      • Hart RG
      • Diener HC
      • Coutts SB
      • Easton JD
      • Granger CB
      • O'Donnell MJ
      • et al.
      Embolic strokes of undetermined source: the case for a new clinical construct.
      ]. ESUS is comprised of several vascular and cardiac sources of emboli including atrial cardiopathy, valvular disease, patent foramen ovale (PFO) and left ventricular disease which represent the majority of the potential causes of ESUS [
      • Ntaios G
      • Perlepe K
      • Lambrou D
      • Sirimarco G
      • Strambo D
      • Eskandari A
      • et al.
      Prevalence and overlap of potential embolic sources in patients with embolic stroke of undetermined source.
      ,
      • Ntaios G
      • Wintermark M
      • Michel P.
      Supracardiac atherosclerosis in embolic stroke of undetermined source: the underestimated source.
      ,
      • Ntaios G
      • Weng SF
      • Perlepe K
      • Akyea R
      • Condon L
      • Lambrou D
      • et al.
      Data-driven machine-learning analysis of potential embolic sources in embolic stroke of undetermined source.
      ,
      • Ntaios G
      • Pearce LA
      • Veltkamp R
      • Sharma M
      • Kasner SE
      • Korompoki E
      • et al.
      Potential embolic sources and outcomes in embolic stroke of undetermined source in the navigate-ESUS trial.
      ,
      • Ntaios G
      • Papavasileiou V
      • Milionis H
      • Makaritsis K
      • Manios E
      • Spengos K
      • et al.
      Embolic strokes of undetermined source in the Athens stroke registry: a descriptive analysis.
      ].
      To read this article in full you will need to make a payment

      References

        • Hart RG
        • Diener HC
        • Coutts SB
        • Easton JD
        • Granger CB
        • O'Donnell MJ
        • et al.
        Embolic strokes of undetermined source: the case for a new clinical construct.
        Lancet Neurol. 2014; 13: 429-438
        • Ntaios G
        • Perlepe K
        • Lambrou D
        • Sirimarco G
        • Strambo D
        • Eskandari A
        • et al.
        Prevalence and overlap of potential embolic sources in patients with embolic stroke of undetermined source.
        J Am Heart Assoc. 2019; 8e012858
        • Ntaios G
        • Wintermark M
        • Michel P.
        Supracardiac atherosclerosis in embolic stroke of undetermined source: the underestimated source.
        Eur Heart J. 2021; 42: 1789-1796
        • Ntaios G
        • Weng SF
        • Perlepe K
        • Akyea R
        • Condon L
        • Lambrou D
        • et al.
        Data-driven machine-learning analysis of potential embolic sources in embolic stroke of undetermined source.
        Eur J Neurol. 2021; 28: 192-201
        • Ntaios G
        • Pearce LA
        • Veltkamp R
        • Sharma M
        • Kasner SE
        • Korompoki E
        • et al.
        Potential embolic sources and outcomes in embolic stroke of undetermined source in the navigate-ESUS trial.
        Stroke. 2020; 51: 1797-1804
        • Ntaios G
        • Papavasileiou V
        • Milionis H
        • Makaritsis K
        • Manios E
        • Spengos K
        • et al.
        Embolic strokes of undetermined source in the Athens stroke registry: a descriptive analysis.
        Stroke. 2015; 46: 176-181
        • Murphy SP
        • Kakkar R
        • McCarthy CP
        • Januzzi JL.
        Inflammation in heart failure: JACC state-of-the-art review.
        J Am Coll Cardiol. 2020; 75: 1324-1340
        • Diener H-C
        • Sacco RL
        • Easton JD
        • Granger CB
        • Bernstein RA
        • Uchiyama S
        • et al.
        Dabigatran for prevention of stroke after embolic stroke of undetermined source.
        N Engl J Med. 2019; 380: 1906-1917
        • Hart RG
        • Sharma M
        • Mundl H
        • Kasner SE
        • Bangdiwala SI
        • Berkowitz SD
        • et al.
        Rivaroxaban for stroke prevention after embolic stroke of undetermined source.
        N Engl J Med. 2018; 378: 2191-2201
        • Sagris D
        • Georgiopoulos G
        • Perlepe K
        • Pateras K
        • Korompoki E
        • Makaritsis K
        • et al.
        Antithrombotic treatment in cryptogenic stroke patients with patent foramen ovale.
        Stroke. 2019; 50: 3135-3140
        • Wen-Yi Huang M
        • Ovbiagele B.
        • Lee M.
        Oral anticoagulants vs antiplatelets in cryptogenic stroke with potential cardiac emboli: meta-analysis.
        Eur J Internal Med. 2021; (PhDMD, FRCP)https://doi.org/10.1016/j.ejim.2021.08.002
        • Ntaios G.
        Embolic stroke of undetermined source: JACC review topic of the week.
        J Am Coll Cardiol. 2020; 75: 333-340
        • Healey JS
        • Gladstone DJ
        • Swaminathan B
        • Eckstein J
        • Mundl H
        • Epstein AE
        • et al.
        Recurrent stroke with rivaroxaban compared with aspirin according to predictors of atrial fibrillation: secondary analysis of the NAVIGATE ESUS randomized clinical trial.
        JAMA Neurol. 2019; 76: 764-773
        • Kamel H
        • Longstreth Jr, WT
        • Tirschwell DL
        • Kronmal RA
        • Broderick JP
        • Palesch YY
        • et al.
        The AtRial cardiopathy and antithrombotic drugs in prevention after cryptogenic stroke randomized trial: rationale and methods.
        Int J Stroke. 2019; 14: 207-214
        • Noubiap JJ
        • Agbaedeng TA
        • Kamtchum-Tatuene J
        • Fitzgerald JL
        • Middeldorp ME
        • Kleinig T
        • et al.
        Rhythm monitoring strategies for atrial fibrillation detection in patients with cryptogenic stroke: a systematic review and meta-analysis.
        IJC Heart Vasc. 2021; 34100780
        • Ntaios G
        • Perlepe K
        • Lambrou D
        • Sirimarco G
        • Strambo D
        • Eskandari A
        • et al.
        Identification of patients with embolic stroke of undetermined source and low risk of new incident atrial fibrillation: the AF-ESUS score.
        Int J Stroke. 2021; 16: 29-38
        • Kitsiou A
        • Sagris D
        • Schäbitz WR
        • Ntaios G.
        Validation of the AF-ESUS score to identify patients with embolic stroke of undetermined source and low risk of device-detected atrial fibrillation.
        Eur J Intern Med. 2021; 89: 135-136
        • Ntaios G
        • Papavasileiou V
        • Lip GY
        • Milionis H
        • Makaritsis K
        • Vemmou A
        • et al.
        Embolic stroke of undetermined source and detection of atrial fibrillation on follow-up: how much causality is there?.
        J Stroke Cerebrovasc Dis. 2016; 25: 2975-2980
        • Svendsen JH
        • Diederichsen SZ
        • Højberg S
        • Krieger DW
        • Graff C
        • Kronborg C
        • et al.
        Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial.
        Lancet. 2000; 398: 1507-1516
        • Vemmos K
        • Ntaios G
        • Savvari P
        • Vemmou AM
        • Koroboki E
        • Manios E
        • et al.
        Stroke aetiology and predictors of outcome in patients with heart failure and acute stroke: a 10-year follow-up study.
        Eur J Heart Fail. 2012; 14: 211-218
        • Ntaios G
        • Vemmos K
        • Lip GY.
        Oral anticoagulation versus antiplatelet or placebo for stroke prevention in patients with heart failure and sinus rhythm: Systematic review and meta-analysis of randomized controlled trials.
        Int J Stroke. 2019; 14: 856-861
        • Sagris D
        • Leventis I
        • Georgiopoulos G
        • Korompoki E
        • Makaritsis K
        • Vemmos K
        • et al.
        Bleeding risk comparison between direct oral anticoagulants at doses approved for atrial fibrillation and aspirin: systematic review, meta-analysis and meta-regression.
        Eur J Intern Med. 2020; 79: 31-36
        • Hsu C
        • Hutt E
        • Bloomfield DM
        • Gailani D
        • Weitz JI.
        Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week.
        J Am Coll Cardiol. 2021; 78: 625-631